Trial Scorecards

THEMIS

Researchers evaluated the effect of twice-daily ticagrelor (Brilinta, AstraZeneca) on CV death, MI or stroke in patients with type 2 diabetes.

Researchers evaluated the effect of twice-daily ticagrelor (Brilinta, AstraZeneca) on CV death, MI or stroke in patients with type 2 diabetes.